Compass Pathways PLC Sponsored ADR $CMPS Shares Sold by Stableford Capital II LLC

Stableford Capital II LLC reduced its position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 43.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,873 shares of the company’s stock after selling 69,266 shares during the period. Stableford Capital II LLC’s holdings in Compass Pathways were worth $1,300,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CMPS. EverSource Wealth Advisors LLC boosted its position in Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Compass Pathways in the fourth quarter valued at $38,000. Parallel Advisors LLC increased its position in shares of Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of Compass Pathways during the 3rd quarter worth $41,000. Finally, North Star Investment Management Corp. raised its stake in shares of Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after buying an additional 7,000 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CMPS has been the topic of a number of research reports. Compass Point set a $25.00 price objective on shares of Compass Pathways in a research note on Tuesday, July 7th. Oppenheimer restated an “outperform” rating and set a $20.00 target price on shares of Compass Pathways in a research report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a report on Friday, July 17th. Wolfe Research reiterated an “outperform” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Finally, Maxim Group increased their price target on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.36.

Compass Pathways Stock Performance

NASDAQ CMPS opened at $11.25 on Tuesday. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways PLC Sponsored ADR has a fifty-two week low of $3.97 and a fifty-two week high of $15.40. The business has a fifty day moving average of $12.52 and a 200-day moving average of $9.19. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -3.57 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. As a group, analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.